Abstracts tagged "treatment"

Abstract Number: 515 • 2019 ACR/ARP Annual Meeting
Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib
Michael Weinblatt¹, Glen Thomson ², Kun Chen ³, Sebastian Meerwein ⁴, Casey Schlacher ⁵ and John Cush ⁶, ¹Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, ²CIADS Research, Winnipeg, Canada, ³AbbVie Inc., North Chicago, ⁴AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁵AbbVie Inc., North Chicago, IL, ⁶5Baylor University Medical Center, Dallas
Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, demonstrated efficacy in the SELECT-BEYOND study in patients (pts) with moderate to severe rheumatoid arthritis (RA) on a stable…
Abstract Number: 1138 • 2019 ACR/ARP Annual Meeting
Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices
Colin Edgerton¹, Janna Radtchenko ² and V. Michael Holers ³, ¹Articularis Healthcare, Charleston, ²Trio Health, La Jolla, CA, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver
Background/Purpose: RA is an autoimmune disease affecting over 1.5 million Americans. Biologic disease-modifying antirheumatic drugs (bDMARDs) expanded treatment choices for RA patients (pts) in the…
Abstract Number: 1432 • 2019 ACR/ARP Annual Meeting
Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –
Shintaro Hirata¹, Takuji Omoto ¹, Hiroki Kohno ¹, Hirofumi Watanabe ¹, Kazutoshi Yukawa ¹, Tadahiro Tokunaga ¹, Tatsuomi Kuranobu ¹, Katsuhiro Oi ¹, Yusuke Yoshida ¹, Tomohiro Sugimoto ¹, Sho Mokuda ¹, Keisuke Oda ¹, Takaki Nojima ¹ and Eiji Sugiyama ¹, ¹Hiroshima University, Hiroshima, Japan
Background/Purpose: To determine whether prednisolone (PSL) could be tapered or discontinued without deterioration of disease control through optimizing methotrexate (MTX) for 2-yrs in patients with…
Abstract Number: 2402 • 2019 ACR/ARP Annual Meeting
Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis?
Martin Schaefer¹, Jörn Kekow ², Karin Rockwitz ³, Anke Liebhaber ⁴, Angela Zink ⁵ and Anja Strangfeld ⁶, ¹German Rheumatism Research Center, Berlin, Germany, ²Otto von Guericke University Magdeburg and Helios Clinic Vogelsang-Gommern, Vogelsang-Gommern, Germany, ³Rheumatologist, Goslar, Germany, ⁴Rheumatologist, Halle/ Salle, Germany, ⁵German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, ⁶German Rheumatism Research Center (DRFZ), Berlin, Germany
Background/Purpose: The satisfaction of rheumatoid arthritis (RA) patients with their pharmacological therapy is a relevant patient reported outcome which influences treatment adherence and continuation. However,…
Abstract Number: 517 • 2019 ACR/ARP Annual Meeting
A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Mark Genovese¹, Kurt de Vlam ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, Iyabode Tiamiyu ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, David Walker ⁶, Tsutomu Takeuchi ⁷ and Kenneth Kalunian ⁸, ¹Stanford University, Stanford, CA, ²Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Northumbria Healthcare, Northumbria, United Kingdom, ⁷Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁸Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA
Background/Purpose: There is an unmet medical need to treat RA in patients who have failed prior biologic DMARD treatments (biologic DMARD inadequate response; bDMARD-IR), some…
Abstract Number: 1193 • 2019 ACR/ARP Annual Meeting
EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis
Gabrielle Barbera¹, Jasleen Kahlon ², Manank Patel ³, Scott Pompa ⁴ and Arundathi Jayatilleke ¹, ¹Drexel, Philadelphia, PA, ²Hahnemann, Philadelphia, PA, ³Rutgers, New Brunswick, NJ, ⁴Dartmouth, Lebanon, NH
Background/Purpose: Undertreatment of RA can lead to cumulative joint damage as well as negatively impact emotional health. Recent evidence favors a treat-to-target strategy to achieve…
Abstract Number: 1437 • 2019 ACR/ARP Annual Meeting
Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease
Sho Sasaki¹, Akira Ishii ², Mai Sugiyama ², Yuto Izumi ², Yoko Nakagome ², Kazuki Hirano ³, Takayoshi Kurabayashi ¹, Noriko Sasaki ², Chiho Yamada ² and Shinji Sato ⁴, ¹Tokai Universitiy School of Medicine, Isehara, Japan, ²Tokai University School of Medicine, Isehara, Japan, ³Tokai University School of Medicine, Isehara, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of complication in patients with rheumatoid arthritis (RA) and its presence often has an effect on the management…
Abstract Number: 2403 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³ and Daisuke Kato ³, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in studies of Japanese, Korean and Taiwanese patients with RA. This analysis of…
Abstract Number: 518 • 2019 ACR/ARP Annual Meeting
Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
Mark Genovese¹, Bernard Combe ², Stephen Hall ³, Andrea Rubbert-Roth ⁴, Sheng Zhong ⁵, Sebastian Meerwein ⁶, Aileen Pangan ⁷ and Roy Fleischmann ⁸, ¹Stanford University, Stanford, CA, ²CHU Montpellier, Montpellier University, Montpellier, France, ³Monash University and Emeritus Research, Melbourne, Australia, ⁴Kantonsspital St. Gallen, St Gallen, Switzerland, ⁵AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁶AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In patients (pts) with active rheumatoid arthritis (RA) and inadequate response or intolerance to bDMARDs, treatment with upadacitinib (UPA), a JAK1-selective inhibitor resulted in…
Abstract Number: 1302 • 2019 ACR/ARP Annual Meeting
Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
Marc C. Hochberg¹, John Carrino ², Thomas Schnitzer ³, Ali Guermazi ⁴, Eric Vignon ⁵, David Walsh ⁶, Alexander White ⁷, Satoru Nakajo ⁸, Robert Fountaine ⁹, Anne Hickman ⁹, Glenn Pixton ¹⁰, Lars Viktrup ¹¹, Mark T. Brown ⁹, Christine R. West ⁹ and Kenneth M. Verburg ⁹, ¹University of Maryland School of Medicine, Baltimore, MD, ²Hospital for Special Surgery, New York, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Boston Medical Center, Boston, ⁵Université Claude Bernard Lyon 1, Lyon, France, ⁶Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, ⁷Progressive Medical Research, Port Orange, FL, ⁸Nakajo Orthopaedic Clinic, Miyagi, Japan, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Morrisville, NC, ¹¹Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tanezumab is a monoclonal antibody that inhibits nerve growth factor and is under investigation for chronic pain treatment. Tanezumab administered intravenously was effective and…
Abstract Number: 1438 • 2019 ACR/ARP Annual Meeting
Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study
Toshihisa Kojima¹, Shuji Asai ¹, Masahiro Hanabayashi ², Masatoshi Hayashi ³, Nobunori Takahashi ¹, Yachiyo Kuwatsuka ⁴, Masahiko Ando ⁴ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Ichinomiya Municipal Hospital, Ichinomiya, Japan, ³Hayashi Orthopedic Clinic, Nagano, Japan, ⁴Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Biological DMARD (bDMARD) concomitant with methotrexate (MTX) has made great progress in the treatment of rheumatoid arthritis (RA) in these decades. There are various…
Abstract Number: 2536 • 2019 ACR/ARP Annual Meeting
Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States
Thierry Dervieux¹, Kelley Brady ¹, Don Thomas ², John Conklin ¹, Eugene Fung ³, Claudia Ibarra ¹ and Michelle Petri ⁴, ¹Exagen, Vista, CA, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Arthritis & Osteoporosis Clinic, Waco, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapeutic drug monitoring of whole blood Hydroxychloroquine (HCQ) can help identify patients at risk of flares due to underexposure (e.g. severe non-adherence, < 200…
Abstract Number: 522 • 2019 ACR/ARP Annual Meeting
Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis
Thierry Sornasse¹, Jeremy Sokolove ¹ and Iain McInnes ², ¹AbbVie Immunology Clinical Development, Redwood City, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) with an inadequate response (IR) to…
Abstract Number: 1329 • 2019 ACR/ARP Annual Meeting
Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Kevin Winthrop¹, Mark Genovese ², Bernard Combe ³, Yoshiya Tanaka ⁴, Alan Kivitz ⁵, Franziska Matzkies ⁶, Beatrix Bartok ⁶, Lei Ye ⁶, Ying Guo ⁶, Chantal Tasset ⁷, John Sundy ⁶, Edward Keystone ⁸, Rene Westhovens ⁹, William F.C. Rigby ¹⁰ and Gerd Burmester ¹¹, ¹Oregon Health and Science University, Portland, OR, ²Stanford University, Stanford, CA, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, ⁸Mount Sinai Hospital and University of Toronto, Toronto, Canada, ⁹University Hospitals, Leuven, Belgium, ¹⁰Dartmouth College, Lebanon, NH, ¹¹Charité—University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is an orally administered, selective inhibitor of Janus Kinase 1 (JAK1) that is under development for the treatment of RA and other…
Abstract Number: 1557 • 2019 ACR/ARP Annual Meeting
Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Daniela DiGuiseppe ², Anne Gitte Loft ³, Manuel Pombo-Suarez ⁴, Herman Mann ⁵, Ziga Rotar ⁶, Florenzo Iannone ⁷, Tore Kvien ⁸, Maria José Santos ⁹, Kari K. Eklund ¹⁰, Bjorn Gudbjornsson ¹¹, Catalin Codreanu ¹², Sema Yılmaz ¹³, Johan Askling ¹⁴, Carlos Sánchez-Piedra ¹⁵, Karel Pavelka ⁵, Matija Tomsic ¹⁶, Fabrizio Conti ¹⁷, Joe Sexton ¹⁸, Helena Santos ¹⁹, Nina Trokovic ²⁰, Thorvardur J Love ²¹, Ruxandra IONESCU ²², Yavuz Pehlivan ²³, Michael J. Nissen ²⁴, Gary Macfarlane ²⁵, Irene van der Horst-Bruinsma ²⁶, Stylianos Georgiadis ²⁷, Lykke Midtbøll Ørnbjerg ²⁸, Cecilie Heegaard Brahe ²⁸, Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁴Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ⁷Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁸Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹¹Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ¹⁴Karolinska Institutet, Stockholm, Sweden, ¹⁵Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁶Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ¹⁷Sapienza University of Rome, Rome, Italy, ¹⁸Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁹Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ²⁰Helsinki University Central Hospital, Helsinki, Finland, ²¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²²SPITALUL CLINIC SFANTA MARIA, Bucharest, ²³Uludağ University, Bursa, Turkey, ²⁴University Hospital Geneva, Geneva, Switzerland, ²⁵University of Aberdeen, Aberdeen, United Kingdom, ²⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁷DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Secukinumab represents a relatively new approach to treating patients with psoriatic arthritis (PsA) and has shown promising results in RCTs. However, there is a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.